Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KINGFISHER phase 3 trial of brolucizumab versus aflibercept in diabetic macular edema
MOH_2019-07-21_007153Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2019
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diabetic macular edema (DME) comparing Brolucizumab 6 mg with Aflibercept 2 mg (2 arms). Started Jun 2019; status: completed.
02
Drugs
brolucizumabaflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on MOH_2019-07-21_007153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-07-21_007153.